This AF4-derived peptide is capable of disrupting the AF4–AF9 complex both in vitro and in vivo, inhibiting the proliferation of leukemia cells (via apoptosis) with chromosomal translocation expressing MLL–AF4 fusion genes [44]. The gene discussed is KMT2A; the disease is leukemia.